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Purpose: Prostate cancer is a common cancer in men in the world. It is rapidly increasing. This study
investigated the incidence and mortality of prostate cancer and the relationship with the Human
Development Index (HDI) and its dimensions in Asia in 2012.
Methods: The study was conducted based on data from the world data of cancer and the World Bank
(including the HDI and its components). The standardized incidence and mortality rates of prostate
cancer were calculated for Asian countries. The correlation between incidence, mortality rates, and the
HDI and its components were assessed with the use of the correlation test, using SPSS software.
Results: There was a total of 191,054 incidences and 81,229 death were recorded in Asian countries in
2012. Among the Asian countries, the ﬁve countries with the highest standardized incidence rates of
prostate cancer were Israel, Turkey, Lebanon, Singapore, and Japan, and the ﬁve countries with the
highest standardized mortality rates were Turkey, Lebanon, Timor-Leste, Armenia, and the Philippines.
The correlation between standardized incidence rate of prostate cancer and the HDI was 0.604
(P 0.001), with life expectancy at birth 0.529 (P¼ 0.002), with mean years of schooling 0.427
(P¼ 0.001), and with level of income per each person of the population 0.349 (P¼ 0.013). Also, between
the standardized mortality rate and the HDI, it was 0.228 (P¼ 0.127).
Conclusions: A signiﬁcant and positive correlation was observed between the standardized incidence
rate of prostate cancer, and the HDI and its dimensions, such as life expectancy at birth, mean years of
schooling, and income level of the population per each person of population. However, there was no
signiﬁcant correlation between the standardized mortality rate, and the HDI and its dimensions.
Copyright © 2015 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer is the sixth most common cancer in the world,
the second most common cancer in men, and the most common
cancer in men in Europe, North America, and parts of Africa.1,2 The
number of new cases estimated was 513,000 patients in 2000,
while the number of new cases estimated was 1.1 million people in
2012. This suggests an increased incidence of prostate cancer in the
past decade.3,4 It is expected that by 2030,1.7 million new cases andgy and Biostatistics,
Sciences, Tehran, Iran.
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known as the most common cancer in men in the future.4 This
cancer includes 15% of all new cancer cases in men. Approximately
70% of all new cases of the cancer occur in developed countries.3
Fortunately, many people survive for many years after diagnosis.
This means that cancer registration systems encompass only the
two ends of the spectrum of the disease and are inadequate to
determine the true burden of the disease.6 The incidence rate of
prostate cancer differs about 50 times in various populations. The
lowest incidence of the disease is seen in Asian countries, and
included 14% of all cases in 2008, especially in Tianjin, China (1.9/
100,000 person-years). The highest incidence occurred in North
America and Scandinavia, especially in African-American peopley Elsevier. This is an open access article under the CC BY-NC-ND license (http://
Prostate Int 3 (2015) 135e140136(137/100,000 person-years).1,7 This might be due to the availability
of screening tests used for diagnosis such as prostate speciﬁc an-
tigen (PSA), and other factors, including nutrition, genetics, life-
style, environmental factors, physical activity, smoking, race, and
cancer registry systems.8e10 The incidence of prostate cancer is
directly correlated with age. Almost 75% of new cancer cases occur
in people older than 85 years. In other words, incidence of this
cancer increases with the increase in life expectancy.1,11 However,
the cause of this cancer is unknown.9 One of the earliest methods of
detection of this cancer is PSA,7 which has been used to screen since
the late 1980s. After using the test, a signiﬁcant increase was
observed in the incidence of prostate cancer in 1990; then, the
steep of increasing the cancer was less.12 The level of development
is one of the factors that greatly affects the distribution of prostate
cancer. In developed countries, prostate cancer is themost common
cancer in men, while in less developed countries, the incidence is
lower than that of other cancers.6 This relationship can also be
considered in the context of socioeconomics in communities.
People with a higher socioeconomic level have a higher incidence
of the cancer.13 Several studies suggest an impact of awareness and
level of income on the distribution of mortality from this type of
cancer. People with a low awareness and low incomes are more
likely to die from prostate cancer. These factors are barriers to
treatment of cancer in these individuals.14e16
The role of the HDI, and the incidence and mortality of prostate
cancer have been considered in a number of studies.17 Information
on the incidence and mortality of prostate cancer can be useful for
medical planning and research activities. According to the possible
role of the HDI, the aim of this study was to investigate the inci-
dence and mortality of prostate cancer and the relationship with
the HDI and its dimensions in Asia in 2012.
2. Materials and methods
This study was an ecologic study in Asia for assessment of the
correlation between the age-speciﬁc incidence and mortality rate
(ASR) and the HDI and its details that include: life expectancy at
birth, mean years of schooling, and gross national income (GNI) per
capita. Data about the ASR for every Asian country for the year 2012
is obtained from the global cancer project available at http://
globocan.iarc.fr/Default.aspx and data about the HDI is obtained
from the Human Development Report 201318 that includes infor-
mation about the HDI and its details for every country in the world
for the year 2012.
2.1. Method of estimate of the ASRs in the global cancer project by
the international agency for research on cancer
2.1.1. Age-speciﬁc incidence rate estimate
The methods of estimation are country-speciﬁc and the quality
of the estimation depends upon the quality and on the amount of
information available for each country. In theory, there are as many
methods as countries, and because of the variety and the
complexity of these methods, an overall quality score for the inci-
dence and mortality estimates combined is almost impossible to
establish. However an alphanumeric scoring system which inde-
pendently describes the availability of incidence and mortality data
has been established at the country level. The combined score is
presented together with the estimates for each country, with an
aim of providing a broad indication of the robustness of the
estimation.
The methods to estimate the sex- and age-speciﬁc incidence
rates of cancer for a speciﬁc country fall into one of the following
broad categories, in the following order of priority: (1) rates pro-
jected to 2012 (38 countries); (2) most recent rates applied to the2012 population (20 countries); (3) estimated from national mor-
tality by modelling, using incidence mortality ratios derived from
recorded data in country-speciﬁc cancer registries (13 countries);
(4) estimated from national mortality estimates by modelling, us-
ing incidence mortality ratios derived from recorded data in local
cancer registries in neighboring countries (9 European countries);
(5) estimated from national mortality estimates using modelled
survival (32 countries); (6) estimated as the weighted average of
the local rates (16 countries); (7) one cancer registry covering part
of a country is used as representative of the country proﬁle (11
countries); (8) age/sex-speciﬁc rates for “all cancers” were parti-
tioned using data on relative frequency of different cancers (by age
and sex) (12 countries); and (9) the rates are those of neighboring
countries or registries in the same area (33 countries).19e21
2.1.2. Age-speciﬁc mortality rate estimate
Depending on the degree of detail and accuracy of the national
mortality data, six methods have been utilized in the following
order of priority: (1) rates projected to 2012 (69 countries); (2)
most recent rates applied to the 2012 population (26 countries); (3)
estimated as the weighted average of regional rates (1 country); (4)
estimated from national incidence estimates by modelling, using
country-speciﬁc survival (2 countries); (5) estimated from national
incidence estimates using modelled survival (83 countries); and (6)
the rates are those of neighboring countries or registries in the
same area (3 countries).19e21
2.2. HDI
The HDI is a composite measure of indicators along three di-
mensions: life expectancy, educational attainment, and command
over the resources needed for a decent living. All groups and re-
gions have seen notable improvement in all HDI components, with
faster progress in low and medium HDI countries. On this basis, the
world is becoming less unequal. Nevertheless, national averages
hide large variations in human experience. Wide disparities remain
within countries of both the North and the South; income
inequality within and between many countries has been rising.17
2.3. Statistical analysis
In this study, we used to the correlation bivariate method for
assessment of the correlation between the ASR and the HDI and its
details that include: life expectancy at birth, mean years of
schooling, and GNI per capita. Statistical signiﬁcance was assumed
if P< 0.05. All reported P values are two-sided. Statistical analyses
were performed using SPSS (version 15.0, SPSS Inc., Chicago, IL,
USA).
3. Results
A total of 191,054 prostate cancer cases were recorded in Asian
countries in 2012. The ﬁve countries with the highest number of
patients were Japan (55,970 cases), China (46,745 cases), India
(19,095 cases), Indonesia (13,663 cases), and Turkey (12,650 cases),
respectively. The ﬁve countries include a total of 148,123 cases,
77.52 percentage of all cases in Asia.
Among Asian countries, the ﬁve countries with the highest
standardized incidence rates of prostate cancer were: Israel with
84.3/100,000, Turkey with 40.6/100,000, Lebanon with 37.2/
100,000, Singapore with 33.1/100,000, and Japan with 30.4/
100,000. The ﬁve countries with the lowest standardized incidence
rates of the cancer were Bhutan with 1.2/100,000, Nepal with 1.5/
100,000, Bangladesh with 1.7/100,000, Uzbekistan with 2/100,000,
and Turkmenistan with 2.1/100,000 (Table 1 and Fig. 1).
Table 1
Number, crude, and standardized incidence and mortality rates of prostate cancer in Asian countries in 2012 (sorted by age standardized rates from highest to lowest).
Prostate e estimated incidence, all ages Prostate e estimated mortality, all ages
Population N Crude rate ASR (W) Population N Crude rate ASR (W)
Israel 4,134 108.8 84.3 Turkey 7,231 19.5 22.8
Turkey 12,650 34.0 40.6 Lebanon 411 19.6 17.1
Lebanon 807 38.5 37.2 Timor-Leste 33 5.5 14.2
Singapore 1,212 45.8 33.1 Armenia 269 18.6 13.1
Japan 55,970 90.9 30.4 The Philippines 2,580 5.3 11.3
Republic of Korea 10,351 42.7 30.3 State of Palestine 83 3.8 10.3
Armenia 476 32.9 27.4 Indonesia 9,191 7.5 9.8
Brunei 29 13.9 21.8 Kazakhstan 494 6.3 8.6
Georgia 570 28.1 18.6 Jordan 164 4.9 8.3
The Philippines 4,858 10.0 18.0 Syrian Arab Republic 484 4.5 7.7
Timor-Leste 42 6.9 16.5 Georgia 278 13.7 7.6
Jordan 285 8.6 15.3 Brunei 9 4.3 7.0
State of Palestine 130 6.0 15.2 Bahrain 15 1.8 6.5
Kazakhstan 1,021 13.0 14.9 Iraq 398 2.4 6.4
Indonesia 13,663 11.2 14.8 Israel 395 10.4 6.3
Kuwait 112 6.5 14.5 Oman 43 2.5 6.3
Bahrain 39 4.6 13.5 Islamic Republic of Iran 2,297 6.0 6.2
Qatar 40 2.7 13.2 Qatar 13 0.9 6.0
Islamic Republic of Iran 4,111 10.7 12.6 United Arab Emirates 26 0.5 5.6
Syrian Arab Republic 738 6.9 11.9 Cambodia 144 2.0 5.0
Malaysia 1,186 8.0 10.8 Japan 11,644 18.9 5.0
Oman 77 4.5 10.2 Kyrgyzstan 71 2.6 4.8
United Arab Emirates 89 1.6 10.0 Saudi Arabia 321 2.0 4.8
Saudi Arabia 703 4.4 9.5 Malaysia 501 3.4 4.6
Iraq 556 3.3 8.7 Republic of Korea 1,696 7.0 4.6
Azerbaijan 301 6.4 8.5 Singapore 169 6.4 4.5
Kyrgyzstan 126 4.7 7.3 Azerbaijan 170 3.6 4.5
Thailand 3,182 9.3 7.2 Pakistan 2,356 2.6 3.9
Maldives 8 4.9 6.4 Afghanistan 194 1.1 3.7
Cambodia 189 2.7 5.6 Thailand 1,700 5.0 3.7
China 46,745 6.6 5.3 Myanmar 597 2.5 3.4
Pakistan 3,041 3.3 5.3 Kuwait 24 1.4 3.0
Myanmar 755 3.1 4.3 Maldives 5 3.1 3.0
India 19,095 2.9 4.2 India 12,231 1.9 2.7
Afghanistan 237 1.4 3.7 Lao PDR 45 1.4 2.7
Lao PDR 60 1.9 3.5 China 22,603 3.2 2.5
Vietnam 1,275 2.9 3.4 Vietnam 872 2.0 2.5
Mongolia 26 1.9 3.4 Yemen 97 0.8 2.3
Republic of Korea 355 2.9 3.2 Mongolia 17 1.2 2.1
Sri Lanka 362 3.5 3.0 Tajikistan 32 0.9 1.9
Yemen 122 0.9 2.7 Sri Lanka 207 2.0 1.6
Tajikistan 47 1.4 2.3 Uzbekistan 129 0.9 1.5
Turkmenistan 37 1.5 2.1 Turkmenistan 22 0.9 1.5
Uzbekistan 189 1.4 2.0 Republic of Korea 146 1.2 1.3
Bangladesh 923 1.2 1.7 Bangladesh 717 0.9 1.2
Nepal 127 0.8 1.5 Nepal 103 0.7 1.2
Bhutan 3 0.8 1.2 Bhutan 2 0.5 0.7
ASR, age-speciﬁc incidence and mortality rate.
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cancer was 81,229 cases. The ﬁve countries with the highest
number of deaths were China (22,603 cases), India (12,231 cases),
Japan (11,644 cases), Indonesia (9,191 cases), and Turkey (7,231
cases). The countries included a total of 62,900 cases (77.43%) of the
total mortality in Asia.
In the Asian countries, the ﬁve countries with the highest
standardized mortality rates from prostate cancer were Turkey
with 22.8/100,000, Lebanon with 17.1/100,000, Timor-Leste with
14.2/100,000, Armenia with 13.1/100,000, and the Philippines with
11.3/100,000. The ﬁve countries which had the lowest standardized
mortality rates from the cancer were Bhutan with 0.7/100,000,
Nepal with 1.2/100,000, Bangladesh with 1.2/100,000, Republic of
Korea with 1.3/100,000, and Turkmenistan with 1.5/100,000
(Table 1 and Fig. 1).
In Table 2, amounts related to the HDI and its dimensions for
each of the Asian countries (sorted based on the HDI) are shown.
Asian countries are classiﬁed according to the HDI as follows: threecountries in the very high category, four countries in the high
category, 35 countries in the middle category, three countries in the
low category, and one country in the unknown category.3.1. Standardized incidence rate and HDI
A positive correlation was seen between the standardized inci-
dence rate of prostate cancer and HDI of ~0.604. This association
was statistically signiﬁcant (P¼ 0.001). There was also a positive
correlation between the standardized incidence rate of the cancer
and dimensions of HDI. In other words, there was a positive cor-
relation between the standardized incidence rate and life expec-
tancy at birth of ~0.529 (P¼ 0.002), A positive correlation between
the standardized incidence rate and mean years of schooling of
~0.427 (P¼ 0.001), and a positive correlation between the stan-
dardized incidence rate and the level of income per each person of
the population equal to 0.349 (P¼ 0.013; Fig. 2).
Fig. 1. Standardized incidence and mortality rate of prostate cancer in Asia in 2012. ASR, age-speciﬁc incidence and mortality rate.
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There was a positive correlation between the standardized
mortality rate for prostate cancer and HDI of ~0.228 which was not
signiﬁcant (P¼ 0.127). There was also a positive correlation be-
tween the standardized mortality rate of the cancer and the di-
mensions of HDI which was not signiﬁcant. There was a positive
correlation of 0.125 between the standardized mortality rate of the
cancer and expectancy at birth (P¼ 0.604), a positive correlation of
0.139 between the standardized mortality rate of the cancer and
mean years of schooling (P¼ 0.357), and a positive correlation of
between the standardized mortality rate of the cancer and the level
of income per each person of population (R ¼ 0.044 and p ¼ 0.77),
which was not signiﬁcant (Fig. 3).
4. Discussion
Prostate cancer is associated with a large dispersion in inci-
dence and death in Asian countries. The evidence suggests an
increase in the burden of disease in this region in the future.6 More
than 60% of the world’s population lives in Asia, and most coun-
tries in the region are developing. The cancer in the continent is
expected to dramatically increase. Therefore, health macro policies
to deal with this cancer in the future are an important
requirement.22
Our ﬁndings showed that the incidence of prostate cancer in
Asian countries is related to HDI, which determines the progress of
a country in three dimensions; life expectancy, level of education,
and the mean income. Countries such as Israel, Turkey, Lebanon,
Singapore, Japan, and Republic of Korea had the highest stan-
dardized incidences of prostate cancer. According to the HDI, the
countries are in the very high and high categories. By contrast,
Tajikistan, Turkmenistan, Uzbekistan, Bangladesh, Nepal, and
Bhutan had the lowest standardized incidences of prostate cancer.
All of these countries in terms of the HDI are in the middle and low
categories. Other studies have shown that the incidence of prostatecancer is greater in countries with high HDI.17,22 This may be due to
lifestyle, diet, and most importantly, public access to PSA and an
existing cancer registry system.2 Also, differences in average life
expectancy, Western foods high in calories and fat, and medical
checkup for prostate cancer in Asian countries, may explain the
difference in incidence in different countries.23
Life expectancy at birth is one of the dimensions of HDI. It is
associated with all types of cancers, especially prostate cancer.
Most cases of prostate cancer occur in old age, especially after 85
years.9 Reports revealed that Japan, Republic of Korea, Singapore,
and Israel have the highest life expectancy at birth in Asian coun-
tries.24 However, in this study, these countries had a high rank in
the incidence of prostate cancer among all of the Asian countries. In
countries with high life expectancy associated with development,
the deaths due to infectious diseases decrease. Hence, the possi-
bility that more people reach old age is enhanced and the risk of
cancer, especially prostate cancer, increases.11 Such results were
seen in other studies.1,12 According to other research, the incidence
of prostate cancer is higher in urban areas than in rural areas in
some Asian countries.25
Another dimension of the HDI is the level of education or
awareness. A signiﬁcant associationwas seen between the low level
of knowledge and the level of PSA.14 Multiple linear regression
analysis showed that inmenwith low levels of education compared
withmenwho had high levels of education, PSA higher than 20mg/
mL was twice.16 People with higher education have a proper diet,
more physical activity, better job opportunities, and low exposure
to other risk factors for prostate cancer.9
One of the dimensions of the HDI is adequate income, which is
speciﬁed by gross domestic product. Bray et al17also indicated that
with rising income levels and improved levels of development,
people have better access to diagnostic services and screening tests,
such as PSA. As a result, many subclinical cases are detected and the
incidence of the disease increases. Access to diagnostic methods
and the screening test using PSA rise with increasing income levels
and improved socioeconomic status.13
Table 2
Human Development Index and its components in Asian countries in 2012.
Population Human Development
Index (HDI)
Life expectancy
at birth
Mean year of
schooling
Gross national
income (GNI) per capita
Very high human
development
Japan 0.912 83.6 11.6 32,545
Republic of Korea 0.909 80.7 11.6 28,231
Israel 0.9 81.9 11.9 26,224
Singapore 0.895 81.2 10.1 52,613
Brunei 0.855 78.1 8.6 45,690
Qatar 0.834 78.5 7.3 87,478
United Arab Emirates 0.818 76.7 8.9 42,716
High human
development
Bahrain 0.796 75.2 9.4 19,154
Kuwait 0.79 74.7 6.1 52,793
Saudi Arabia 0.782 74.1 7.8 22,616
Malaysia 0.769 74.5 9.5 13,676
Kazakhstan 0.754 67.4 10.4 10,451
Georgia 0.745 73.9 12.1 5,005
Lebanon 0.745 72.8 7.9 12,364
Islamic Republic of Iran 0.742 73.2 7.8 10,695
Azerbaijan 0.734 70.9 11.2 8,153
Oman 0.731 73.2 5.5 24,092
Armenia 0.729 74.4 10.8 5,540
Turkey 0.722 74.2 6.5 13,710
Sri Lanka 0.715 75.1 9.3 5,170
Medium human
development
Jordan 0.7 73.5 8.6 5,272
China 0.699 73.7 7.5 7,945
Turkmenistan 0.698 65.2 9.9 7,782
Thailand 0.69 74.3 6.6 7,722
Maldives 0.688 77.1 5.8 7,478
Mongolia 0.675 68.8 8.3 4,245
State of Palestine 0.67 73 8 3,359
Philippines 0.654 69 8.9 3,752
Uzbekistan 0.654 68.6 10 3,201
Syrian Arab Republic 0.648 76 5.7 4,674
Indonesia 0.629 69.8 5.8 4,154
Kyrgyzstan 0.622 68 9.3 2,009
Tajikistan 0.622 67.8 9.8 2,119
Viet Nam 0.617 75.4 5.5 2,970
Iraq 0.59 69.6 5.6 3,557
Timor-Leste 0.576 62.9 4.4 5,446
India 0.554 65.8 4.4 3,285
Cambodia 0.543 63.6 5.8 2,095
Lao PDR 0.543 67.8 4.6 2,435
Bhutan 0.538 67.6 2.3 5,246
Low human
development
Bangladesh 0.515 69.2 4.8 1,785
Pakistan 0.515 65.7 4.9 2,566
Myanmar 0.498 65.7 3.9 1,817
Nepal 0.463 69.1 3.2 1,137
Yemen 0.458 65.9 5.3 928
Afghanistan 0.374 49.1 3.1 1,000
Other countries or
territories
Republic of Korea e e e e
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cancer mortality rates in Asian countries and the HDI and its di-
mensions. In countries with lower HDI, medical checkup for pros-
tate cancer is low and in countries with higher HDI, PSA screening
and medical checkup for prostate cancer is high. So, the diagnostic
rate of asymptomatic prostate cancer in early stages would be
lower in lower HDI countries. Considering the lower screening rate
in the lower HDI countries and the result of no signiﬁcant differ-
ence in the mortality between the developed and the developing
countries, the conclusion of this study seems to reﬂect the meta-
analysis results, which is “Although PSA screening leads to over-
diagnosis and over-treatment of prostate cancer, it does not
contribute decreasing both prostate cancer-speciﬁc and overall
mortality. Although the diagnostic rate of early stage prostate
cancer by PSA screening is higher in the Asian developed countries
with higher HDI, it would not improve prostate cancer-speciﬁc
survival rate so much and would not lead to a signiﬁcant differ-
ence in cancer mortality compared to the developing countries
without an adequate screening system for prostate cancer.23There are various effective factors such as nutrition, occupation
environmental risk factors, smoking, lifestyle, and demographic
factors, including age, genetic susceptibility, and socioeconomic
situation, on prostate cancer.8,10 However, the main cause of this
cancer is unknown.9 Any variation in the incidence of prostate
cancer and its relationship with macroeconomic determinants
should be cautiously interpreted. The effect of these factors will
also be considered.17
To detect early prostate cancer, screening tests should be used.
Digital rectal examination (DRE) is one of the tests, which is easy.
Given the low sensitivity of the test, prostate speciﬁc antigen (PSA)
is another test recommended. PSA is commonly applied in the
world and increases the incidence of prostate cancer (due to the
diagnosis of cancer cases in the latent period). However, it reduces
death.7,26,27
This was an ecological study. The ecological fallacy will occur if
results are inferred and concluded at the individual level. The re-
sults of this study are attributable only at the population level.
However, it should be stated that the cancer registry system in Asia
Fig. 2. Correlation between the Human Development Index and standardized inci-
dence of prostate cancer in Asia in 2012. HDI, Human Development Index.
Fig. 3. Correlation between the Human Development Index and standardized mor-
tality rates for prostate cancer in Asia in 2012. HDI, Human Development Index.
Prostate Int 3 (2015) 135e140140is still not fully equal in all areas and sometimes differences in the
quality and coverage of data are observed.
In conclusion, the incidence of prostate cancer is high in coun-
tries with greater development. A signiﬁcant and positive correla-
tion was observed between the standardized incidence rate of
prostate cancer, and the HDI and its dimensions, such as life ex-
pectancy at birth, mean years of schooling, and income level of the
population per each person of population. However, there was no
signiﬁcant correlation between the standardized mortality rate,
and the HDI and its dimensions.
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